XTalks
APRIL 7, 2021
The test is intended for the detection of COVID-19 infection, either a recent or previous infection, as detected through an adaptive antibody immune response to SARS-CoV-2. The test involves self-collection of a fingerstick dried blood sample. percent of the time, and negative results agreeing 100 percent of the time.
XTalks
MARCH 10, 2021
Adaptive Biotechnologies’ T-Detect COVID Test is a next-generation sequencing (NGS) test that can indicate recent or prior infection with SARS-CoV-2 through detection of a T cell immune response to the virus. This is the first T cell test of its kind for the detection of COVID-19 infection.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 23, 2020
Cellular (T cell) response were observed to multiple regions of the spike protein including the RBD region. 74% had measurable cellular responses at the 1.0 mg dose group demonstrated cellular responses. The 1.0 mg and 2.0 mg dose group and 84% demonstrating neutralizing antibodies in the 2.0
The Pharma Data
MARCH 25, 2022
Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. W911QY-21-9-0001.
The Pharma Data
MAY 16, 2021
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.
Drug Discovery World
APRIL 14, 2023
Carolyn R Bertozzi, PhD – Outstanding Achievement in Chemistry in Cancer Research Bertozzi is the Baker Family Director of Sarafan ChEM-H, the Anne T and Robert M Bass Professor in the School of Humanities and Sciences, Professor of Chemistry and, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University.
XTalks
SEPTEMBER 14, 2020
The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus.
Expert insights. Personalized for you.
102 
Let's personalize your content